Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.

ABSTRACT:

Abstract

Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T products for clinical treatment of relapsed/refractory acute lymphoblastic leukemia and diffuse large B cell lymphoma in 2017, five more CAR-T cell products were subsequently approved for treating multiple myeloma or B cell malignancies. Moreover, clinical trials of CAR-T cell therapy for treating other hematological malignancies are ongoing. Both China and the United States have contributed significantly to the development of clinical trials. However, CAR-T cell therapy has many limitations su

SUBMITTER: Yang Z 

PROVIDER: S-EPMC10538902 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature